Preferred Name |
zanamivir |
|
Synonyms |
Relenza |
|
Definitions |
A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47786" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47786" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000636195 |
|
altLabel |
Relenza |
|
cui |
C0216660 C0876148 |
|
DATE FIRST PUBLISHED |
2009-02-20 |
|
Date last modified |
2009-09-18 |
|
definition |
A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47786" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47786" NCI Thesaurus) |
|
LT |
TRD |
|
NCI ID |
C47786 |
|
notation |
CDR0000636195 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
zanamivir |
|
tui |
T109 T121 |